All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Lars BullingerDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Lars Bullinger, Charité – Universitätsmedizin Berlin, Berlin, DE, about the highlights for measurable residual disease (MRD) assessment in AML from ASH 2020.
ASH 2020: Highlights for MRD assessment in AML
Bullinger mentions three studies presented at ASH 2020: the first one investigating the effectiveness of MRD eradication with chemotherapy prior to allogeneic stem cell transplantation in AML; the second study evaluating NPM1 as a molecular marker for MRD; and the last one focusing on new technologies for MRD assessment.
Bullinger kindly gave his interview in German, with the title 'ASH 2020: Highlights zum MRD Monitoring bei der AML'.